MAP2K7 and melanoma: The benefit of using RT in melanoma as adjuvant treatment has become particularly controversial in recent years given the promising results associated with the use of modern systemic therapies such as immune checkpoint and BRAF/MEK inhibitors, several of which have been approved for resected stage IIB, IIC, and III melanoma (17).